
    zero accrual
  
['advanced lymphoma', 'advanced malignant solid neoplasm', 'hematopoietic and lymphoid cell neoplasm', 'refractory lymphoma', 'refractory malignant solid neoplasm', 'refractory plasma cell myeloma']
['dasatinib']

        Inclusion Criteria:

          -  Patients must have met applicable eligibility criteria in the Master MATCH Protocol
             prior to registration to treatment subprotocol

          -  Patients must have one of the following missense mutations in DDR2: S768R, I638F,
             L239R

          -  Patients must have an electrocardiogram (ECG) within 8 weeks prior to treatment
             assignment and must have no clinically important abnormalities in rhythm, conduction
             or morphology of resting ECG (e.g. complete left bundle branch block, third degree
             heart block)

          -  Patients with known left ventricular dysfunction must have an echocardiogram (ECHO) or
             a nuclear study (multigated acquisition scan [MUGA] or First Pass) within 4 weeks
             prior to registration to treatment and must not have left ventricular ejection
             fraction (LVEF) < institutional lower limit of normal (LLN). If the LLN is not defined
             at a site, the LVEF must be > 50% for the patient to be eligible

        Exclusion Criteria:

          -  Patients must not have known hypersensitivity to dasatinib or compounds of similar
             chemical or biologic composition

          -  Patients with prior use of dasatinib will be excluded

          -  Dasatinib should NOT be given in the presence of STRONG CYP 3A4 inhibitors/inducers.
             Patients who take these drugs concurrently are ineligible for treatment with
             dasatinib. These drugs must be discontinued prior to initiation of dasatinib

          -  Dasatinib should NOT be given in the presence of H2-antagonists or proton pump
             inhibitors. Patients who take these drugs concurrently are ineligible for treatment
             with dasatinib. These drugs must be discontinued prior to initiation of dasatinib.
             Antacids taken 2 hours before or after dasatinib administration can be used in place
             of H2-antagonists or proton pump inhibitors if some acid-reducing therapy is needed
      